LENSAR (Orlando, FL), which develops femtosecond laser technology forrefractive surgery, has received U.S. FDA clearance for its LENSAR laser system with Streamline IV, expanding the platform's capabilities to include the creation of microradial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery.
Microradial incisions performed with the system are guided by the femtosecond laser platform's imaging capabilities. Fully programmable for depth, length, and position by the surgeon based upon the patient's biometric data, microradial incisions are used to treat additional corneal conditions.
"The addition of the microincisional capability to the existing suite of enhancements for managing astigmatism, including arcuate incisions, increases the value of the LENSAR laser system in delivering on the expectations of the premium cataract procedure," says F. Beau Swann, MD, MS, of Brazos Eye Surgery of Texas. "Particularly for those patients who are not candidates for a LASIK or SMILE procedure, this latest LENSAR innovation offers the surgeon an additional option to improve a patient's result and, ultimately, level of satisfaction with their choice of a customized, advanced procedure."
Swann is participating in the rollout incorporating microradial incisions into refractive cataract treatment planning with the LENSAR laser system. The initial data collection will be conducted at two sites. The company has applied for regulatory approval for microradial incisions in the EU and anticipates the in-market availability of the new feature pending approval.
For more information, please visit www.lensar.com.